Related Experiment Video
Updated: Aug 9, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Edaravone inhibits the disease activity in rheumatoid arthritis
Kaoru Arii1, Yoshitaka Kumon, Yukio Ikeda
1Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Japan. ariik@med.kochi-u.ac.jp
Journal of Clinical Pharmacy and Therapeutics
|April 26, 2006
Summary
Edaravone, a free radical scavenger, showed potential in managing rheumatoid arthritis (RA) symptoms and reducing inflammation markers in a stroke patient. Further randomized controlled trials are recommended to confirm its efficacy for RA treatment.
Area of Science:
- Rheumatology
- Neurology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and pain.
- Acute stroke is a serious neurological event that can occur in patients with RA.
- Edaravone is a free radical scavenger with potential anti-inflammatory properties.
Observation:
- A male patient with rheumatoid arthritis experienced an acute stroke.
- The patient was treated with edaravone, a free radical scavenger.
- Following edaravone administration, polyarthralgia improved, and serum C-reactive protein levels decreased.
Findings:
- Edaravone treatment led to a reduction in rheumatoid arthritis disease activity, as indicated by a decrease in the Disease Activity Score 28 (DAS28).
- The patient's polyarthralgia (joint pain) improved concurrently with reduced C-reactive protein (CRP) concentration.
- These observations suggest edaravone may possess disease-modifying effects in rheumatoid arthritis.
Implications:
- Edaravone demonstrates potential as a novel therapeutic agent for controlling rheumatoid arthritis activity.
- The findings warrant further investigation through well-designed randomized controlled trials to establish edaravone's efficacy and safety in RA patients.
- This research opens avenues for exploring neuroprotective and anti-inflammatory agents in the management of complex autoimmune and neurological conditions.
Related Concept Videos
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...